The parties will identify and design probiotic bacteria that
produce highly sustainable quantities of microbial metabolites,
known to improve human health and vitality
BOSTON and REHOVOT, Israel, Feb. 6, 2024
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE:
EVGN), a leading computational biology company targeting to
revolutionize life-science product development across multiple
market segments, and Verb Biotics LLC., a microbiome health
ingredient company whose mission is to improve human health,
entered into a collaboration agreement that will focus on the
development of new strains of probiotic bacteria, which produce a
highly sustainable quantity of microbial metabolites that improve
human health and vitality. The collaboration will focus on
identifying and enhancing the currently unknown genetic pathways in
microbes that support the production of novel metabolites, using
Evogene's MicroBoost AI tech-engine and Verb Biotics'
extensive accumulated knowledge in the field of the microbiome.
The probiotics market is expected to double and reach
approximately $114 billion by 2031
from approximately $55 billion in
2022[i]. The increased awareness of the microbiome, the
bacteria living in and on the human body, has sparked significant
interest in microbiome products based on supporting microbes for a
healthier lifestyle. This collaboration aligns with the expanding
importance of global microbiome research.
The collaboration generates excellent synergy by combining
Evogene's knowledge in bacterial-based product development
utilizing its tech-engine MicroBoost AI with Verb Biotic's
access to the genomes of various microbial strains that support the
production of microbial metabolites vital for human health.
The financial terms of the agreement are not disclosed.
"Partnering with Evogene equips Verb Biotics with a powerful
edge to revolutionize microbiome-driven health solutions. By
leveraging Evogene's technology, we further streamline and de-risk
our innovation pathway, prioritizing function-first approaches for
optimal microbiome health", says Noah
Zimmerman, CTO at Verb Biotics.
Eyal Ronan, EVP of Business
Development at Evogene, noted, "This collaboration underscores
Evogene's strategic commitment to leveraging our state-of-the-art
AI tech-engines to new areas and opens doors for additional sectors
in the life sciences industry to benefit from our powerful
technology. Together with Verb Biotics, we aim to drive substantial
progress in probiotics innovation and to stretch the boundaries of
what can be achieved in this field."
About Verb Biotics:
Verb Biotics is a microbiome health ingredient company whose
mission is to improve human health. Verb "biotics" ingredients are
developed to deliver specific metabolites with targeted mechanisms
of action to address functional health categories such as
foundational gut microbiome health, gut-brain health, and healthy
metabolism. From discovery to scale, the company applies science,
biotechnology, and intentional development to deliver probiotics,
postbiotics, and synbiotics for the business-to-business functional
food, beverage, and dietary supplement industries.
To learn more, please visit us at www.verbbiotics.com and follow
us on LinkedIn.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass
AI and GeneRator AI – leveraging Big Data
and Artificial Intelligence and incorporating deep
multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of
products based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com.
Forward-Looking Statements:
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates" or words of similar meaning. For example, Verb
Biotics, Evogene and its subsidiaries are using forward-looking
statement in this press release when they discuss the development
of new strains of probiotic bacteria, which produce a high
sustainable quantity of microbial metabolites that improve human
health and vitality, the expected growth of the probiotics market,
and the expanding importance of the global microbiome
research. Such statements are based on current
expectations, estimates, projections and assumptions, describe
opinions about future events, involve certain risks and
uncertainties which are difficult to predict and are not guarantees
of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, those risk factors contained in
Evogene's reports filed with the applicable securities authority.
Evogene and its subsidiaries disclaim any obligation or commitment
to update these forward-looking statements to reflect future events
or developments or changes in expectations, estimates, projections,
and assumptions.
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
[i] [i]
https://finance.yahoo.com/news/global-probiotics-market-size-worth-075000774.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACfgMfcGAd9Vb25h7wBya_9UoIBrvxPf-M_28cco_CEOoBNp4NNeiBr5PK4MLAvxvrsrp3saUS0HQEnfb_bs_bRaM18fgQl5KaqrFUoiBEOB9csgNepnnEmTexxUU8wUWRventc4qyBfoiXoQsZmhn64WZLY6DqlWJEchD4bJxHm
Logo
- https://mma.prnewswire.com/media/1947468/Evogene.jpg
Logo - https://mma.prnewswire.com/media/2335165/VerbBiotics.jpg
View original
content:https://www.prnewswire.com/news-releases/evogene-and-verb-biotics-enter-collaboration-agreement-to-advance-probiotic-innovation-302054575.html
SOURCE Evogene Ltd.; Verb Biotics LLC.